State of the science for myelodysplastic syndrome: Prognosis and promise of new therapies

Best Practice and Research: Clinical Haematology

Volumn 17, Issue 4 SPEC.ISS., 2004, Pages 535-541

  Rowe, Jacob M ^a  

^a RAMBAM MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANGIOGENESIS INHIBITOR; ANTHRACYCLINE; ARSENIC TRIOXIDE; AZACITIDINE; CYCLOSPORIN; CYTARABINE; CYTOTOXIC AGENT; DNA METHYLTRANSFERASE; ENDOSTATIN; ERYTHROPOIETIN; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; GLYCOPROTEIN P INHIBITOR; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HISTONE DEACETYLASE INHIBITOR; MATRIX METALLOPROTEINASE INHIBITOR; MONOCLONAL ANTIBODY; MULTIDRUG RESISTANCE PROTEIN; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RADIOISOTOPE; THALIDOMIDE; TOPOTECAN; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNINDEXED DRUG; VALSPODAR; VASCULOTROPIN INHIBITOR; ZOSUQUIDAR;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BLOOD TRANSFUSION; CANCER SURVIVAL; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG POTENTIATION; HUMAN; MALIGNANT TRANSFORMATION; MEDICAL DECISION MAKING; MYELODYSPLASTIC SYNDROME; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH EXCESS BLASTS IN TRANSFORMATION; RISK ASSESSMENT; STEM CELL TRANSPLANTATION;

EID: 5744225231     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2004.08.006     Document Type: Article

References (21)

1. A. Ganser D. Hoelzer Clinical course of myelodysplastic syndromes Hematology/Oncology Clinics of North America 6 1992 607-618
2. G. Leone L. Mele A. Pulsoni et al. The incidence of secondary leukemias Haematologica 84 1999 937-945
3. C. Aul A. Giagounidis U. Germing Epidemiological features of myelodysplastic syndromes: results from regional cancer surveys and hospital-based statistics International Journal of Hematology 73 2001 405-410
4. J.M. Bennett D. Catovsky M.T. Daniel et al. Proposals for the classification of the myelodysplastic syndromes British Journal of Haematology 51 1982 189-199
5. J.W. Vardiman N.L. Harris R.D. Brunning The World Health Organization (WHO) classification of the myeloid neoplasms Blood 100 2002 2292-2302
6. N.L. Harris E.S. Jaffe J. Diebold et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House Virginia, November 1997 Journal of Clinical Oncolology 17 1999 3835-3849
7. C. Aul N. Gattermann A. Heyll et al. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system Leukemia 6 1992 52-59
8. G.J. Mufti J.R. Stevens D.G. Oscier et al. Myelodysplastic syndromes: a scoring system with prognostic significance British Journal of Haematology 59 1985 425-433
9. G.F. Sanz M.A. Sanz T. Vallespi et al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients Blood 74 1989 395-408
10. C. Aul N. Gattermann U. Germing et al. Risk assessment in primary myelodysplastic syndromes: validation of the Dusseldorf score Leukemia 8 1994 1906-1913
11. P. Greenberg C. Cox M.M. LeBeau et al. International scoring system for evaluating prognosis in myelodysplastic syndromes Blood 89 1997 2079-2088
12. NCCN practice guidelines for the myelodysplastic syndromes. National Comprehensive Cancer Network Oncology (Huntingt) 12 1998 53-80
13. B.D. Cheson J.M. Bennett H. Kantarjian et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes Blood 96 2000 3671-3674
14. M.S. Gordon Advances in supportive care of myelodysplastic syndromes Seminars in Hematology 36 1999 21-24
15. A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes British Journal of Haematology 103 1998 1070-1074
16. E. Hellstrom-Lindberg T. Ahlgren Y. Beguin et al. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients Blood 92 1998 68-75
17. L.R. Silverman E.P. Demakos B.L. et al. Peterson Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B Journal of Clinical Oncology 20 2002 2429-2440
18. A.B. Kornblith J.E. Herndon L.R. Silverman et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study Journal of Clinical Oncology 20 2002 2441-2452
19. E.E. Cameron K.E. Bachman S. Myohanen et al. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer Nature Genetics 21 1999 103-107
20. G. Leone L. Teofili M.T. Voso et al. DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias Haematologica 87 2002 1324-1341
21. A. List M. Beran J. DiPersio et al. Opportunities for Trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes Leukemia 17 2003 1499-1507